Posted by Michael Wonder on 17 May 2022
MHRA approves faricimab through international work-sharing initiative
17 May 2022 - It is the first treatment approved by the UK regulator that has been made possible through the Access Consortium ‘New Active Substance Work Sharing Initiative’.
Faricimab, a new medicine for people with the progressive eye diseases wet age-related macular degeneration and visual impairment due to diabetic macular oedema, has been approved by the MHRA.
It is the first treatment approved by the UK regulator that has been made possible through the Access Consortium ‘New Active Substance Work Sharing Initiative’ – a collaboration of regulatory authorities including the United Kingdom, Australia, Canada, Singapore, and Switzerland.
